Risks and benefits of activated protein C treatment for severe sepsis. - Wikidata - wikimedia - TriplyDB

Risks and benefits of activated protein C treatment for severe sepsis.

Risks and benefits of activated protein C treatment for severe sepsis.

http://www.wikidata.org/entity/Q34151715

about

Clinical trials in severe sepsis with drotrecogin alfa (activated)Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia Recombinant human activated protein C for severe sepsis in neonates Human recombinant activated protein C for severe sepsis Recombinant human activated protein C for severe sepsis in neonates Assessment of six mortality prediction models in patients admitted with severe sepsis and septic shock to the intensive care unit: a prospective cohort study Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study.Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposure.Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.Therapeutic interventions in sepsis: current and anticipated pharmacological agents An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?Anti-inflammatory strategies for the treatment of sepsis.Medical guidelines and performance measures: the need to keep them free of industry influence.Patience and change: a conflict of interests?The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.Activated protein C in septic shock: a propensity-matched analysis Management of severe sepsis: integration of multiple pharmacologic interventions.Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.Update on the treatment of disseminated intravascular coagulation.Drotrecogin alfa: a role in emergency department treatment of severe sepsis?Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.Pathophysiology of acute renal failure in sepsis.History of evidence-based medicine. Oranges, chloride of lime and leeches: barriers to teaching old dogs new tricks.The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.Drotrecogin alfa (activated): real-life use and outcomes for the UK The pathogenesis of sepsis.Drotrecogin alpha (activated): the treatment for severe sepsis?Model for predicting short-term mortality of severe sepsis Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.Septic shock: the changing Zeitgeist of management.

P2860

Q21195024-DFDCE0BA-DB91-451C-9B3D-D02C90D3F95F Q21261838-E7E84282-7AB9-44BC-85B7-0AA918E1BF8B Q24200439-3BD9160C-B518-40E1-9BB5-7B4AA28FB109 Q24242859-BCDB4AE8-8BC5-4C80-B362-A1E0284F22F2 Q24246064-B1C6D163-04E0-49FA-A967-84F084C661B3 Q24796183-553DC528-814F-4798-A504-8B9022F2246F Q24802551-13361D4F-02AC-4F0B-BB5C-28BA964EE868 Q25255548-E650D6FC-3ACA-49E4-A6F1-E2D3C14D3CEA Q30788622-6F675D22-06BA-4ED8-A8F8-0095343DA4C9 Q33338424-879C4603-8CA2-4BA9-8EB7-DB228FF8DAAD Q33813616-940223E7-6456-4C47-BE05-F0DAE3DE642A Q34058113-B0391C49-2645-4249-929B-63DB957A111C Q34297740-56AF9A30-1A24-48C4-B675-1E3290E72459 Q34370297-1ACFCE25-50AD-4375-9F73-EC0A05CDF4A1 Q34427050-1AABF2D8-7A59-4B7F-A338-6BDCA3883396 Q34486385-9A6D1490-7AFE-4CBD-B7CA-0E2D73780E76 Q34568205-BF426BC7-4311-4497-B902-023EC65EF1BF Q35093632-8E4D750D-5DE5-4122-A5DC-03E8547307FE Q35307754-FB786C3C-75C9-446B-95D6-06E06C3844B0 Q35544754-0ED7A6FE-5166-4015-8FA5-CD9163669564 Q35548184-42616DBE-9481-419A-9F05-A7C639CCA167 Q35559424-6DA2D3C4-120B-4937-B55B-EE7865191AC1 Q35585233-AF9A4102-7170-4BF4-8F2A-01AEA07EAA8A Q35794980-BA04D258-9B14-4C4E-9906-62468B8CC971 Q35809195-781231BA-830A-4541-97A2-EA73C7CAFF9A Q35850483-7815F77F-E911-42EB-ADA6-84F8EAD61E4C Q35925664-652F638F-6A0F-479C-A7D1-30299749BA25 Q35983230-56028CF0-C64D-4370-A37A-D0C1DFCED663 Q36223556-88471E86-3A05-4776-BF90-7A686D23C6BF Q36467579-A6B554C9-B8F0-423F-A9F2-288596DF394B Q36744024-63FB03C4-C55B-4C74-AA2D-9EC98044D27B Q36749140-1E43A81A-4329-4046-AA93-87A951F32148 Q36934401-9041C14F-61BC-4AA8-9EC3-0903BFAF6B5B Q36981698-6E05DB81-93A9-450B-83CE-F9180D95CFAD Q37279786-6B9A7B71-5912-47F4-8B87-294004C6D410 Q37354434-EF89DDAE-7A06-4FD5-8DA6-854FE9F21DE1 Q37609202-00163352-77D1-4E94-AA6C-EFB8119AE1B5 Q37655890-FD8E81EA-1EAE-40D9-A8F5-42A7A8823C7D Q37953865-45CD28E2-123C-4269-85F2-0B07621B1CDA Q41839400-32803F2F-E4E4-4A90-8107-1E37419C5759

P2860

Risks and benefits of activated protein C treatment for severe sepsis.

http://www.wikidata.org/entity/Q34151715

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Risks and benefits of activated protein C treatment for severe sepsis.

@ast

Risks and benefits of activated protein C treatment for severe sepsis.

@en

Risks and benefits of activated protein C treatment for severe sepsis.

@nl

type

label

Risks and benefits of activated protein C treatment for severe sepsis.

@ast

Risks and benefits of activated protein C treatment for severe sepsis.

@en

Risks and benefits of activated protein C treatment for severe sepsis.

@nl

prefLabel

Risks and benefits of activated protein C treatment for severe sepsis.

@ast

Risks and benefits of activated protein C treatment for severe sepsis.

@en

Risks and benefits of activated protein C treatment for severe sepsis.

@nl

P1433

Q34151715-A123F48F-1F4C-46C2-B185-4D92E2127D55

P1476

Q34151715-569C4B70-12A4-4A52-B208-DDFB40FD4CF1

P2093

Q34151715-000D3B88-D0F7-4BE7-8E97-D96B7FAE65BD

Q34151715-12811A70-4BA6-4CA5-82EF-7345AF47605B

Q34151715-20BD91C5-4DE6-4775-8D35-2DB15AC98F59

Q34151715-67C95942-E94C-45F4-A765-2B0F78C92D92

P304

Q34151715-1D2E50DA-F13C-4B73-8A55-FD6053E682FE

P31

Q34151715-C1CCCB96-8EE2-4295-AB44-1D7F2E1AEEE8

P356

Q34151715-5797D5E3-8BEE-48A4-8346-89B38A40BE77

P407

Q34151715-C9A94963-3E2B-4785-9DD9-2B12E12BC443

P433

Q34151715-9994AFD5-21F0-48C9-8229-7C698699BCC5

P478

Q34151715-FDC7A61A-3C9E-4CF7-BD32-787FFEC449EB

P577

Q34151715-B744DD16-D4DE-4965-B762-5F287827A0D1

P698

Q34151715-2B5E6B8E-F321-4FBF-88D7-E19230EB6FC7

P921

Q34151715-72D434AE-4385-4F6D-8A9C-4DD825E5182A

P356

P1433

The New England Journal of Medicine

P1476

Risks and benefits of activated protein C treatment for severe sepsis.

@en

P2093

Anthony F Suffredini

http://www.w3.org/2001/XMLSchema#string

H Shaw Warren

http://www.w3.org/2001/XMLSchema#string

Peter Q Eichacker

http://www.w3.org/2001/XMLSchema#string

Robert S Munford

http://www.w3.org/2001/XMLSchema#string

P304

1027-1030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMSB020574

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12324562

http://www.w3.org/2001/XMLSchema#string

P921